XML 37 R25.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT INFORMATION
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
Reportable Segments
The following is a brief description of the Company’s reportable segments:
•The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan® product line currently represent approximately 85% of the Salix segment revenues.
•The International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products.
•The Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices.
•The Diversified segment consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) dermatology products, (iii) generic pharmaceutical products and (iv) dentistry products.
•The Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products.
Resources are allocated and performance is assessed by the Company’s CEO, whom the Company has determined to be the Company’s Chief Operating Decision Maker (the “CODM”). The Company’s CODM evaluates the performance of its segments and allocates resources to them based on segment profit. Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, Asset impairments, Restructuring, integration, separation costs, and Other expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.
The CODM uses segment profit in the annual budgeting and forecasting process. The CODM considers budget-to-actual variances on a monthly basis for segment profit when making decisions about allocating capital and personnel to the segments. The CODM uses segment profit in determining the compensation of certain employees. In assessing segment performance and managing operations, the CODM does not review segment assets.
Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company’s businesses and certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. Furthermore, a portion of share-based compensation is considered a corporate cost since the amount of such expense depends on company-wide performance rather than the operating performance of any single segment.
Segment Revenues and Profits
Segment revenues, profits and reconciliation of segment profit to consolidated Loss before income taxes were as follows:
For the three months ended March 31,
SalixInternationalSolta MedicalDiversifiedBausch + LombTotal
(in millions)202520242025202420252024202520242025202420252024
Revenues:
Total revenues$542$499$262$265$113$88$205$202$1,137$1,099$2,259$2,153
Less:
Cost of goods sold (excluding amortization and impairments of intangible assets)434110210927193036481423
Costs of other revenues——1711————11
Selling, general and administrative111102525328254548447405
Research and development17276554342828
Segment profit$371$329$85$87$53$40$127$114$180$242$816$812
Corporate(268)(244)
Amortization of intangible assets(256)(274)
Asset impairments— (1)
Restructuring, integration and separation costs(1)(12)
Other expense, net(15)— 
Operating income276 281 
Interest income11 9 
Interest expense(330)(355)
Gain on extinguishment of debt— 11 
Foreign exchange and other(4)(15)
Loss before income taxes$(47)$(69)
During the three months ended March 31, 2025 and 2024, ten products represented 50% and 48% of total revenues, respectively.